Trial Profile
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms KEYNOTE191
- Sponsors Acerta Pharma
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
- 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.